Study Isolates Virus in Chronic Fatigue Sufferers Print E-mail
By Staff and Wire Reports   
Thursday, 08 October 2009 14:38
ABC News is reporting that a virus linked to prostate cancer also appears to play a role in chronic fatigue syndrome (CFS), this according to research that could lead to drug treatments for a mysterious disorder that affects 17 million people worldwide. Prior this news, BioMedReports had scheduled an interview with Dr. William A. Carter, CEO of Hemispherix Biopharma (AMEX:HEB), whose company is still waiting for approval for it's CFS treatment. That report/interview will appear on BioMedReports during market hours on Friday.

According to the breaking news from Reuters, researchers found the virus, known as XMRV, in the blood of 68 out of 101 chronic fatigue syndrome patients. The same virus showed up in only 8 of 218 healthy people, they reported on Thursday in the journal Science.

Dr. William A. Carter, CEO of Hemispherx BioPharma, Inc. (AMEX:HEB) is expected to share some important news about the company's pending FDA decision for Ampligen as a first line treatment for Chronic Fatigue Syndrome (CFS) and some new information about the company's Alferon LDO (Low Dose Oral) application.

The Company’s products include Ampligen and Alferon N and Injection. Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as a vaccine enhancer(adjuvant) for both therapeutic and preventative vaccine development. Alferon N is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is an application under early stage development targeting influenza and viral diseases. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS.

CFS impairs the immune system and causes incapacitating fatigue, according to the U.S. Centers for Disease Control and Prevention. Sufferers can also experience memory loss, problems with concentration, joint and muscle pain, headaches, tender lymph nodes and sore throats.

Symptoms last at least six months and can be as disabling as multiple sclerosis or rheumatoid arthritis, the CDC said.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter